NCT03686683 2024-10-08
ProVent
Dendreon
Phase 3 Completed
Clinical Trials
21 trialsNCT02159950 2023-04-27
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT01818986 2022-05-06
Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT01804465 2021-08-18
Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer
University of California, San Francisco
Phase 2 Completed
NCT01706458 2021-06-18
Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT01807065 2020-08-25
Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Completed
NCT01560923 2020-04-03
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT01727154 2019-08-19
PRIME
Dendreon
Terminated
NCT01420965 2019-07-10
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
Augusta University
Phase 2 Terminated
NCT01306890 2019-06-07
PROCEED
Dendreon
Completed
NCT01487863 2019-03-19
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
Dendreon
Phase 2 Completed
NCT01981122 2018-10-24
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Dendreon
Phase 2 Completed
NCT00779402 2018-01-29
PROTECT
Dendreon
Phase 3 Completed
NCT01338012 2017-06-05
mCRPC
Dendreon
Phase 2 Terminated
NCT01431391 2017-05-30
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Dendreon
Phase 2 Completed
NCT00715078 2017-05-23
To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen
Dendreon
Phase 2 Completed
NCT01477749 2015-12-09
Sipuleucel-T Manufacturing Demonstration Study
Dendreon
Phase 2 Completed
NCT00715104 2015-05-04
NeoACT
Dendreon
Phase 2 Completed
NCT00005947 2010-11-01
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Dendreon
Phase 3 Completed
NCT01133704 2010-09-08
Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer
Dendreon
Phase 3 Completed
NCT00065442 2010-09-06
ProvengeĀ® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Dendreon
Phase 3 Completed